P608 Crohn’s disease patients with high baseline symptoms achieve clinical remission more rapidly with Budesonide than with Mesalazine
I. Kunz*1, R. Hofmann1
1Tillotts Pharma AG, Rheinfelden, Switzerland
Budesonide (Entocort®) showed non-inferiority compared with Mesalazine (Pentasa®) in Japanese patients with mild-to-moderate active Crohn’s disease (CD) after 8 weeks of treatment.1 The aim of this analysis was to compare 2, 4, and 8 weeks remission rates based on Patient-reported Outcome (PRO) in patients treated with Budesonide (BUD) or Mesalazine (MZ) grouped according to high or low level of symptoms at baseline (week 0).
In a post-hoc sub-group analysis, patients with mild-to-moderate CD on BUD 9 mg/day (
Clinical remission [def 1] was achieved in significantly more patients starting with high BSL (>103) and treated with BUD compared with MZ after 2 weeks (
This post-hoc sub-group analysis reveals that PRO2 is a suitable instrument to detect early improvement of symptoms. Budesonide (Entocort®) showed a more rapid onset of effect compared with Mesalazine (Pentasa®) in patients starting with high baseline symptoms.
1. Yokoyama T,